0
Savara Pharmaceuticals Banner Image

Savara Pharmaceuticals has reached its limit for free report views

Work for Savara Pharmaceuticals? Upgrade Your Profile and unlock all your annual reports.

Savara Pharmaceuticals

  • Ticker SVRA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Savara Pharmaceuticals Logo Image
  • 11-50 Employees
  • Based in Austin, Texas
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affectedMore individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
Savara Pharmaceuticals

Most Recent Annual Report

Savara Pharmaceuticals MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Savara Pharmaceuticals has reached its limit for free report views.

Older/Archived Annual Reports